FDA-cleared profile

Brainomix 360 Triage LVO

Brainomix Limited · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Notification-only, parallel triage of acute-setting brain CTA studies for suspected large-vessel occlusion (LVO), communicating cases to a neurovascular specialist for review; not diagnostic.

Clinical role
Notification-only parallel worklist prioritization for suspected LVO, without image-region marking or removal/deprioritization of cases.
Images and patients
CT/CTA · Brain/head vasculature, specifically terminal ICA and MCA-M1
Key limitation
Keep in mind: Compressed previews are informational and not diagnostic beyond notification; the device is limited to imaging-data analysis, does not replace full patient evaluation, and must not be relied on to make or confirm diagnosis. The device does not mark a specific image location or alter/remove/deprioritize the original worklist case.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Notification-only, parallel triage of acute-setting brain CTA studies for suspected large-vessel occlusion (LVO), communicating cases to a neurovascular specialist for review; not diagnostic.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain/head vasculature, specifically terminal ICA and MCA-M1 Input: DICOM-compliant acute-setting brain CTA images evaluating terminal intracranial ICA and proximal MCA-M1 vessels; no patient-age restriction is stated in the FDA indication.
  • Who uses it?Intended users: Hospital networks and trained clinicians, with notification to neurovascular specialists.
  • What does the software produce?Output: A 'Suspected LVO' priority notification with compressed preview images through mobile application/email and a web user-interface path with unprocessed/straightened images; notified clinicians must review non-compressed images on a diagnostic viewer.
  • What is its most important limitation?Key limitation: Compressed previews are informational and not diagnostic beyond notification; the device is limited to imaging-data analysis, does not replace full patient evaluation, and must not be relied on to make or confirm diagnosis. The device does not mark a specific image location or alter/remove/deprioritize the original worklist case.

Clinical takeaway. Clinical role: Notification-only, parallel triage of acute-setting brain CTA studies for suspected large-vessel occlusion (LVO), communicating cases to a neurovascular specialist for review; not diagnostic.

Evidence takeaway. Evidence from the reviewed source record: FDA packet: standalone retrospective evaluation of 308 CTA scans from 14 U.S. hospitals/clinics, with two ABR-certified neuroradiologists and a third adjudicator. The confusion matrix was TP 126, TN 156, FP 12, FN 14; overall sensitivity was 90.0% (95% CI 84.2%-94.3%), specificity 92.9% (88.0%-94.3%), and ROC AUC 91.4% (88.2%-94.5%). Time-to-notification ranged from 86.3 to 178.2 seconds against a 3.5-minute goal; left/right hemisphere and other subgroup endpoints are separate.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Notification-only, parallel triage of acute-setting brain CTA studies for suspected large-vessel occlusion (LVO), communicating cases to a neurovascular specialist for review; not diagnostic.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Notification-only parallel worklist prioritization for suspected LVO, without image-region marking or removal/deprioritization of cases.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
DICOM-compliant acute-setting brain CTA images evaluating terminal intracranial ICA and proximal MCA-M1 vessels; no patient-age restriction is stated in the FDA indication.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
A 'Suspected LVO' priority notification with compressed preview images through mobile application/email and a web user-interface path with unprocessed/straightened images; notified clinicians must review non-compressed images on a diagnostic viewer.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Clinical/hospital environment and hospital-network acute-care workflow; the comparison table identifies a clinical/hospital environment.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Hospital networks and trained clinicians, with notification to neurovascular specialists.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Compressed previews are informational and not diagnostic beyond notification; the device is limited to imaging-data analysis, does not replace full patient evaluation, and must not be relied on to make or confirm diagnosis. The device does not mark a specific image location or alter/remove/deprioritize the original worklist case.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA packet: standalone retrospective evaluation of 308 CTA scans from 14 U.S. hospitals/clinics, with two ABR-certified neuroradiologists and a third adjudicator. The confusion matrix was TP 126, TN 156, FP 12, FN 14; overall sensitivity was 90.0% (95% CI 84.2%-94.3%), specificity 92.9% (88.0%-94.3%), and ROC AUC 91.4% (88.2%-94.5%). Time-to-notification ranged from 86.3 to 178.2 seconds against a 3.5-minute goal; left/right hemisphere and other subgroup endpoints are separate.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA packet: standalone retrospective evaluation of 308 CTA scans from 14 U.S. hospitals/clinics, with two ABR-certified neuroradiologists and a third adjudicator. The confusion matrix was TP 126, TN 156, FP 12, FN 14; overall sensitivity was 90.0% (95% CI 84.2%-94.3%), specificity 92.9% (88.0%-94.3%), and ROC AUC 91.4% (88.2%-94.5%). Time-to-notification ranged from 86.3 to 178.2 seconds against a 3.5-minute goal; left/right hemisphere and other subgroup endpoints are separate.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Overall standalone LVO endpoint: 90.0% (95% CI 84.2%-94.3%); left-hemisphere subgroup 88.6% (79.4%-94.8%) and right-hemisphere subgroup 91.4% (83.0%-96.7%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

The overall and hemisphere subgroup sensitivities are labeled separately; ROC AUC and time-to-notification remain distinct.

Reported specificity
Overall standalone LVO endpoint: 92.9% (95% CI 88.0%-94.3%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

This is the overall FDA specificity; subgroup specificity values must not be collapsed into the directory fact.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Brainomix 360 Triage LVO regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K231837
  • Samplen=308
  • Sites14
  • IndependenceIndependence not established

K231837

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231837. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM-compliant acute-setting brain CTA images evaluating terminal intracranial ICA and proximal MCA-M1 vessels; no patient-age restriction is stated in the FDA indication.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K231837: Brainomix 360 Triage LVO

  2. Routing

    Source context, not route validation: The FDA packet describes a DICOM-compliant software package on an off-the-shelf physical or virtual server integrated with the Brainomix 360 Platform, receiving data from DICOM-compliant imaging devices and providing mobile-app and web-user-interface notifications; exact local interface versions and compatibility are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K231837: Brainomix 360 Triage LVO

  3. AI processing

    Source context, not route validation: The exact FDA package describes Brainomix 360 Triage LVO running on an off-the-shelf physical or virtual server installed within a hospital network, with results sent to the Brainomix 360 cloud service and notifications delivered to users' mobile devices. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Brainomix 360 Triage LVO is a radiological computer aided triage and notification (CADt) software package compliant with the DICOM standard and running on an off-the-shelf physical or virtual server." … "Both proposed and predicate devices run on standard physical and/or virtual servers which are installed within a hospital network and within the protection of hospital firewalls.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K231837: Brainomix 360 Triage LVO

  4. Returned objects

    Source context, not route validation: A 'Suspected LVO' priority notification with compressed preview images through mobile application/email and a web user-interface path with unprocessed/straightened images; notified clinicians must review non-compressed images on a diagnostic viewer.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K231837: Brainomix 360 Triage LVO

  5. Viewer/worklist/report

    Unresolved route: A 'Suspected LVO' priority notification with compressed preview images through mobile application/email and a web user-interface path with unprocessed/straightened images; notified clinicians must review non-compressed images on a diagnostic viewer.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K231837: Brainomix 360 Triage LVO

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Brainomix 360 Triage LVO running on an off-the-shelf physical or virtual server installed within a hospital network, with results sent to the Brainomix 360 cloud service and notifications delivered to users' mobile devices. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Brainomix 360 Triage LVO is a radiological computer aided triage and notification (CADt) software package compliant with the DICOM standard and running on an off-the-shelf physical or virtual server." … "Both proposed and predicate devices run on standard physical and/or virtual servers which are installed within a hospital network and within the protection of hospital firewalls.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The FDA packet describes a DICOM-compliant software package on an off-the-shelf physical or virtual server integrated with the Brainomix 360 Platform, receiving data from DICOM-compliant imaging devices and providing mobile-app and web-user-interface notifications; exact local interface versions and compatibility are not established.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Brainomix's current official FAQ describes ISO 27001, GDPR, and DPA controls for the current Brainomix 360 family; this does not establish certificate scope, expiry, deployed configuration, or exact K243294 security controls.
  • Product family
  • Checked 2026-10-25

Obtain current certificate scope, data-processing terms, hosting region, encryption, identity/access, audit, retention, and incident-response evidence for the deployed release.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Brainomix 360 Triage LVO; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231837
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Brain/head vasculature, specifically terminal ICA and MCA-M1
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-09-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K231837 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K231837: Brainomix 360 Triage LVO

    U.S. Food and Drug Administration - Published 2023-09-28 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Brainomix 360 Triage LVO model card (K231837)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Brainomix 360 official FAQ

    Brainomix Limited - Accessed 2026-09-07

    Scope: productFamily, implementationCapabilities, security, training

  8. openFDA exact recall query for K231837

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K231837 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260729

Vascular Assist Occlusion Triage (VAOT) (v1.0)

GuideAI Health

Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support

Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Decision
2026-06-18
FDA-cleared K261317

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Adult head CTA or mCTA triage for suspected complete large-vessel and medium-vessel occlusion.

Modality
CT/CTA
Anatomy
Head/Brain
Decision
2026-05-14
FDA-cleared K252421

JLK-NCCT

JLK, Inc.

Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.

Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Decision
2026-03-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history